|
Upcoming News Zulassungsantrag für Raxone in 1Q oder anfang 2Q Phase 3 Daten für Catena in DMD anfang 2Q Marktkap liegt nach wievor bei rund 12 M€ was unglaublich und brutal billig ist , andere Biotechs sind mit nicht mal annähernd so guten Pipeline um 30 bis 100 fach höher bewertet . Products & Pipeline The lead compound Raxone®/Catena® (INN: idebenone) is being developed in four indications: Leber's Hereditary Optic Neuropathy, in preparation for regulatory re-submission in Europe Duchenne Muscular Dystrophy, in a Phase III study Primary Progressive Multiple Sclerosis (PPMS), in a Phase II study conducted by the US National Institutes of Health Santhera's second compound in clinical development, omigapil, is in preparation for a Phase I pharmacokinetics study in in pediatric patients with Congenital Muscular Dystrophy. The third compound fipamezole for the treatment of Dyskinesia in Parkinson's Disease, is available for licensing of development and world-wide commercialization rights. Raxone® (in Europe) and Catena® (in North America) are trademarks of Santhera Pharmaceuticals for its proprietary idebenone 150 mg tablets. For more information about the availability of Raxone®/Catena® (idebenone) under Named Patient Programs or other Special Access Programs outside the United States click here. |
|
| aus der Diskussion: | Diskussion zu SANTHERA PHARMACEUTICALS HOLDING AG |
| Autor (Datum des Eintrages): | Biohero (05.03.14 12:09:43) |
| Beitrag: | 13 von 14,069 (ID:46567635) |
| Alle Angaben ohne Gewähr © wallstreetONLINE | |